Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9BV57

UPID:
MTND_HUMAN

ALTERNATIVE NAMES:
Acireductone dioxygenase (Fe(2+)-requiring); Acireductone dioxygenase (Ni(2+)-requiring); Membrane-type 1 matrix metalloproteinase cytoplasmic tail-binding protein 1; Submergence-induced protein-like factor

ALTERNATIVE UPACC:
Q9BV57; D6W4Y3; Q53HW3; Q53QD3; Q57YV7; Q68CK2; Q6ZSF7; Q7Z512; Q96P85; Q9NV57

BACKGROUND:
The enzyme Acireductone dioxygenase, known for its requirement of Fe(2+) or Ni(2+) for activity, is integral to both the methionine salvage pathway and unique biochemical reactions. It produces distinct products depending on the metal ion present, highlighting its biochemical flexibility. Additionally, it influences cell migration through MMP14 interaction and is crucial for hepatitis C virus replication in specific contexts.

THERAPEUTIC SIGNIFICANCE:
Exploring Acireductone dioxygenase's multifaceted roles offers a promising avenue for developing novel therapeutic interventions, given its critical functions in metabolism and pathogen support.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.